IN2014DN10548A - - Google Patents

Info

Publication number
IN2014DN10548A
IN2014DN10548A IN10548DEN2014A IN2014DN10548A IN 2014DN10548 A IN2014DN10548 A IN 2014DN10548A IN 10548DEN2014 A IN10548DEN2014 A IN 10548DEN2014A IN 2014DN10548 A IN2014DN10548 A IN 2014DN10548A
Authority
IN
India
Prior art keywords
vaginal
antiprogestins
pertinent
treating
variety
Prior art date
Application number
Inventor
Joseph S Podolski
Kuang Hsu
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48614182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of IN2014DN10548A publication Critical patent/IN2014DN10548A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule comprising one or more antiprogestins.
IN10548DEN2014 2012-05-31 2013-05-30 IN2014DN10548A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653674P 2012-05-31 2012-05-31
PCT/US2013/043447 WO2013181449A1 (en) 2012-05-31 2013-05-30 Formulations and methods for vaginal delivery of antiprogestins

Publications (1)

Publication Number Publication Date
IN2014DN10548A true IN2014DN10548A (en) 2015-08-21

Family

ID=48614182

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10548DEN2014 IN2014DN10548A (en) 2012-05-31 2013-05-30

Country Status (22)

Country Link
US (1) US10328022B2 (en)
EP (1) EP2854763B1 (en)
JP (1) JP6341910B2 (en)
KR (1) KR102127348B1 (en)
CN (1) CN104334158B (en)
AU (1) AU2013267359C1 (en)
BR (1) BR112014029131B1 (en)
CA (1) CA2872644A1 (en)
CL (1) CL2014003232A1 (en)
CO (1) CO7141411A2 (en)
CR (1) CR20140567A (en)
EA (1) EA030444B1 (en)
ES (1) ES2701400T3 (en)
IL (1) IL235450B (en)
IN (1) IN2014DN10548A (en)
MX (2) MX363640B (en)
NZ (1) NZ702467A (en)
PH (1) PH12014502516B1 (en)
SG (2) SG11201407397WA (en)
UA (1) UA114106C2 (en)
WO (1) WO2013181449A1 (en)
ZA (1) ZA201408262B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
AU2015256473B2 (en) * 2014-05-05 2018-07-12 Allergan pharmaceuticals International Ltd. Formulations and methods for vaginal delivery of antiprogestins
KR20170005819A (en) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 Natural combination hormone replacement formulations and therapies
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
JP2017531026A (en) * 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド Sustained release abuse deterrent liquid filler form
EP3025709B1 (en) 2014-11-27 2020-09-30 Capsugel Belgium NV Dosage form articles for external mucosal applications
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN110678555B (en) 2017-04-14 2023-10-13 比利时胶囊公司 Method for preparing pullulan
AU2018251256B2 (en) * 2017-04-14 2023-10-05 Capsugel Belgium Nv Pullulan capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (en) 1977-01-13 1978-08-11 Roussel Uclaf NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS
FR2521565B1 (en) 1982-02-17 1985-07-05 Dior Sa Parfums Christian PULVERULENT MIXTURE OF LIPID COMPONENTS AND HYDROPHOBIC CONSTITUENTS, METHOD FOR PREPARING SAME, HYDRATED LIPID LAMELLAR PHASES AND MANUFACTURING METHOD, PHARMACEUTICAL OR COSMETIC COMPOSITIONS COMPRISING HYDRATED LAMID PHASES
FR2522328B1 (en) 1982-03-01 1986-02-14 Roussel Uclaf NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
FR2534487B1 (en) 1982-10-15 1988-06-10 Dior Christian Parfums METHOD FOR THE HOMOGENEIZATION OF HYDRATED LIPIDAL LAMELLAR PHASE DISPERSIONS, AND SUSPENSIONS OBTAINED THEREBY
DE3237814A1 (en) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. WATER-FREE EMULSIONS AND USE THEREOF
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
FR2598421B1 (en) 1986-05-06 1988-08-19 Roussel Uclaf NOVEL 19-NOR OR 19-NOR D-HOMO STEROIDS SUBSTITUTED IN POSITION 11B BY A RADICAL PHENYL CARRYING AN ALKYNYL RADICAL, THEIR PREPARATION METHOD, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE4426601A1 (en) 1994-07-27 1996-02-01 Schering Ag Use of a combination product containing a competitive progesterone antagonist and a progestogen for the manufacture of a medicament for the treatment of endometriosis or Leiomyomata uteri
UA37259C2 (en) 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
GB9522403D0 (en) * 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
EP0900234B1 (en) 1996-05-01 2000-07-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1998008471A1 (en) 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US20050070516A1 (en) 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (en) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisable multilayer film for packaging
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
AR025609A1 (en) * 1999-09-13 2002-12-04 Hoffmann La Roche SOLID LIPID FORMULATIONS
UA74168C2 (en) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Use of beta-adrenergic agonist for treating endometriosis and infertility as well as for improving fertility
ATE396197T1 (en) * 2000-03-17 2008-06-15 Us Gov Health & Human Serv 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE WITH ANTIGESTAGENIC ACTIVITY
IN191020B (en) 2000-03-28 2003-09-13 Dabur Res Foundation
US7378406B2 (en) 2000-10-18 2008-05-27 Schering Ag Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
WO2003005954A2 (en) 2001-07-09 2003-01-23 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
JP2005507874A (en) 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド Vaginal delivery of chemotherapeutic agents and membrane efflux system inhibitors for cancer treatment
JP2003143474A (en) 2001-11-02 2003-05-16 Matsushita Electric Ind Co Ltd Video signal processing system
US7417013B2 (en) 2002-05-01 2008-08-26 Mcneil-Ppc, Inc. Warming and nonirritating lubricant compositions and method of comparing irritation
DE602004026173D1 (en) 2003-04-29 2010-05-06 Gen Hospital Corp METHOD AND DEVICES FOR THE DELAYED RELEASE OF SEVERAL MEDICAMENTS
EP1593376A1 (en) * 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
JP5017109B2 (en) 2004-07-09 2012-09-05 ザ・ポピュレイション・カウンシル，インコーポレイテッド Sustained release composition containing a progesterone receptor modulator
GT200500185A (en) 2004-08-09 2006-04-10 PROGESTERONE RECEIVER MODULATORS UNDERSTANDING PIRROL-OXINDOL DERIVATIVES AND THEIR USES
CN101163467B (en) 2005-03-22 2012-07-18 雷普罗斯治疗公司 Pharmaceutical uses for trans-clomiphene
WO2006111856A1 (en) 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
DE102005030294A1 (en) 2005-06-24 2007-01-04 Schering Ag Nonsteroidal progesterone receptor modulators
EP1940413A1 (en) * 2005-09-29 2008-07-09 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
CN1846703A (en) 2006-02-13 2006-10-18 程定超 Vagina administration mifepristone prepn and its composition and prepn process
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
JP2008012281A (en) * 2006-06-05 2008-01-24 Koritsu Shoji:Kk Insertion assisting device
KR20070116538A (en) * 2006-06-05 2007-12-10 유겐가이샤 코리츠 쇼지 Insertion aid
CZ300424B6 (en) * 2006-06-20 2009-05-13 Pliva - Lachema A. S. Pharmaceutical composition for peroral administration
CA2673128C (en) 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
US8105625B2 (en) 2007-04-05 2012-01-31 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
HRP20160689T1 (en) 2007-04-20 2016-07-15 Preglem S.A. SELECTIVE PROGESTERON MODULATORS FOR UTERINE BLOOD TREATMENT
WO2009037704A1 (en) * 2007-09-20 2009-03-26 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
TWI477276B (en) * 2008-04-28 2015-03-21 Repros Therapeutics Inc Antiprogestin dosing regimens
US20130066302A1 (en) * 2009-09-29 2013-03-14 MEDIMETRICS Personalized Drug Delivery B.V. Intrauterine electronic capsule for administering a substance
UA113283C2 (en) 2010-12-23 2017-01-10 19-NORSTEROIDS AND THEIR APPLICATIONS FOR THE TREATMENT OF PROGESTERON-STAINLESS STATES
DE202011110355U1 (en) 2011-03-09 2014-01-15 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of a selective progesterone receptor modulator, an antigestagens or an antigestagen agent
UA113291C2 (en) 2011-08-04 2017-01-10 TRANSCLOMYPHENE METABOLITES AND THEIR APPLICATIONS

Also Published As

Publication number Publication date
BR112014029131B1 (en) 2021-03-09
AU2013267359C1 (en) 2016-09-29
BR112014029131A2 (en) 2018-05-29
KR20150014928A (en) 2015-02-09
JP2015518052A (en) 2015-06-25
IL235450B (en) 2020-02-27
CR20140567A (en) 2015-03-09
CL2014003232A1 (en) 2015-03-13
ZA201408262B (en) 2015-12-23
KR102127348B1 (en) 2020-06-29
NZ702467A (en) 2016-07-29
US10328022B2 (en) 2019-06-25
CA2872644A1 (en) 2013-12-05
PH12014502516A1 (en) 2015-01-12
MX363640B (en) 2019-03-28
WO2013181449A1 (en) 2013-12-05
ES2701400T3 (en) 2019-02-22
CN104334158B (en) 2018-08-10
PH12014502516B1 (en) 2015-01-12
AU2013267359B2 (en) 2016-05-26
CO7141411A2 (en) 2014-12-12
UA114106C2 (en) 2017-04-25
AU2013267359A1 (en) 2014-11-20
MX2019003467A (en) 2019-06-06
EP2854763B1 (en) 2018-09-26
EP2854763A1 (en) 2015-04-08
EA030444B1 (en) 2018-08-31
HK1206622A1 (en) 2016-01-15
IL235450A0 (en) 2014-12-31
EA201492290A1 (en) 2015-03-31
JP6341910B2 (en) 2018-06-13
SG10201704858PA (en) 2017-07-28
CN104334158A (en) 2015-02-04
US20150111862A1 (en) 2015-04-23
MX382986B (en) 2025-03-13
SG11201407397WA (en) 2014-12-30
MX2014014054A (en) 2015-02-12

Similar Documents

Publication Publication Date Title
IN2014DN10548A (en)
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2014DN09434A (en)
MX365939B (en) Nuclear transport modulators and uses thereof.
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201492047A1 (en) PROLIPOSOMAL TESTOSTERONE COMPOSITIONS
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX2015016421A (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease.
MX2015016425A (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease.
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
MX2015004362A (en) Ketamine derivatives.
MX362485B (en) Novel rock inhibitors.
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MD4291B1 (en) Medicinal preparation for the treatment of otitis
MX2012014498A (en) Rosuvastatin pharmaceutical composition.
IN2013MU03123A (en)